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Abstract
Purpose Concomitant treatment with the glucose-lowering
drug metformin and the platelet aggregation inhibitor
dipyridamole often occurs in patients with type 2 diabetes
mellitus who have suffered a cerebrovascular event. The gas-
trointestinal uptake of metformin is mediated by the human
equilibrative nucleoside transporter 4 (ENT4), which is
inhibited by dipyridamole in preclinical studies. We hypothe-
sized that dipyridamole lowers the plasma exposure to
metformin.
Methods Eighteen healthy volunteers (mean age 23 years; 9
male) were randomized in an open-label crossover study.
Subjects were allocated to treatment with metformin 500 mg
twice daily in combination with dipyridamole slow-release
200 mg twice daily or to metformin alone for 4 days. After a
washout period of 10 days, the volunteers were crossed over
to the alternative treatment arm. Blood samples were collected
during a 10-h period after intake of the last metformin dose.
The primary endpoint was the area under the plasma
concentration-time curve (AUC0–12h) and the maximum plas-
ma metformin concentration (Cmax).
Results In healthy subjects, dipyridamole did not significantly
affect Cmax nor AUC0–12h of metformin under steady-state
conditions.
Conclusions Previous in vitro studies report that
dipyridamole inhibits the ENT4 transporter that mediates gas-
trointestinal uptake of metformin. In contrast, co-
administration of dipyridamole at therapeutic dosages to
healthy volunteers does not have a clinically relevant effect
on metformin plasma steady-state exposure. This observation
is reassuring for patients who are treated with this combination
of drugs.
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Introduction
Patients with type 2 diabetes mellitus are at increased risk for
cardiovascular disease and associated cardiovascular events
[1]. The incidence of ischemic stroke is significantly increased
in these patients [2].Metformin, a biguanide glucose-lowering
agent, is the first line oral treatment option in patients with
type 2 diabetes mellitus [3]. The primary mechanism of action
is inhibition of hepatic gluconeogenesis [4]. In addition, there
is preclinical and clinical evidence that metformin has direct
cardiovascular protective properties independent of its
glucose-lowering action [5].
Dipyridamole is registered for the secondary prevention of
cerebral ischemia in combination with acetylsalicylic acid,
since studies have shown that dipyridamole added to
acetylsalicylic acid reduces the incidence of myocardial in-
farction, stroke, or cardiovascular death [6]. Therefore, con-
comitant treatment with metformin and dipyridamole often
occurs in patients with type 2 diabetes who have suffered a
Electronic supplementary material The online version of this article
(doi:10.1007/s00228-016-2039-8) contains supplementary material,
which is available to authorized users.
* N. P. Riksen
niels.riksen@radboudumc.nl
1 Department of Pharmacology-Toxicology, Radboud University
Medical Center, Nijmegen, The Netherlands
2 Department of Pharmacy, Radboud University Medical Center,
Nijmegen, The Netherlands
3 Department of Internal Medicine 463, Radboud University Medical
Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Eur J Clin Pharmacol (2016) 72:725–730
DOI 10.1007/s00228-016-2039-8
cerebrovascular event, and potential pharmacokinetic interac-
tions between these drugs are highly relevant.
Metformin is a highly hydrophilic compound with a net
positive charge at physiologic pH and its absorption, dis-
tribution, and elimination are dependent on active trans-
port by several carrier-mediated transporters [7]. The up-
take of metformin from the gastrointestinal tract is medi-
ated, at least in part, by the human equilibrative nucleo-
side transporter 4 (ENT4; gene SLC29A4), also known as
the plasma membrane monoamine transporter (PMAT) [7,
8]. ENT4 is localized on the apical membrane of
enterocyte villus tips and exhibits great sensitivity to
pH, with an optimal activity at a pH of approximately
6.0 [8, 9]. Renal excretion of metformin is mediated by
the human organic cation transporter hOCT2, which is
expressed on the basolateral membrane of proximal tubu-
lar cells, and by multidrug and toxin extrusion trans-
porters (MATE1 and to a lesser extent MATE2K), which
are present in the apical membrane [7]. Uptake into hepa-
tocytes occurs via hOCT1 and hOCT3, and excretion into
bile is mediated by MATE1 [7, 10]. This is corroborated
by the findings of a profound reduction in the apparent
volume of distribution of metformin in OCT1- and OCT3-
knockout mice [11, 12].
The transport characteristics of ENT4 have been stud-
ied in various in vitro models [9, 13]. Substrate transport
by ENT4 (tested for adenosine and 1-methyl-4-
phenylpyridinium) is s ignif icant ly inhibi ted by
dipyridamole with an IC50 value of approximately
5 μM, which is in the range of the plasma concentration
during normal therapeutic use of dipyridamole [14].
Therefore, by inhibition of the apical ENT4, concomitant
treatment with dipyridamole might result in a lower bio-
availability and plasma concentration of metformin.
The aim of this study was to determine whether concomi-
tant use of dipyridamole reduces the gastrointestinal absorp-
tion of metformin in healthy subjects.
Methods
Participants
Healthy male and female participants between the ages of
18 and 50 years were eligible for enrollment. The includ-
ed participants had to be in good health, free from cardio-
vascular disease, diabetes mellitus and hypertension (sys-
tolic blood pressure ≥140 mmHg and/or diastolic
≥90 mmHg), and non-smoking. We excluded individuals
with renal dysfunction (GFR MDRD <60 ml/min/
1.73 m2), ECG abnormalities, and those who were taking
concomitant medication. Oral contraception use by female
participants was permitted.
Ethics statement
The study was approved by the local ethics committee and
was performed in the Radboud University Medical Center in
compliance with the recommendations of the Declaration of
Helsinki. We obtained written informed consent from all vol-
unteers before participation. Preparation, conduct, and analy-
sis of this trial complied with Good Clinical Practice guide-
lines. This trial was prospectively registered at www.
clinicaltrials.gov (NCT01613755).
Experimental design
In a prospective randomized open-label two-period crossover
study, subjects were allocated to treatment with either metfor-
min hydrochloride 500 mg (Mylan, Bunschoten,
The Netherlands) twice daily in combination with
dipyridamole slow release 200 mg (Boehringer Ingelheim,
Alkmaar, The Netherlands) twice daily, both for 4 days to
ensure a steady-state plasma concentration, or to metformin
500mg alone twice daily for 4 days. After a washout period of
10 days, the volunteers were crossed over to the alternative
treatment arm. An independent researcher performed simple
random allocation by the use of sealed envelopes. We studied
the interaction between metformin and dipyridamole at
steady-state for both drugs, because this more accurately re-
flects common clinical practice. To demonstrate that a steady-
state plasma concentration was reached, blood was drawn in
the morning of the third treatment day and fourth day, imme-
diately before intake of the morning dose of dipyridamole and
1 h later, which was just before the morning dose of metfor-
min, to determine the trough plasma concentration of
dipyridamole and metformin, respectively. On the fourth treat-
ment day, the subjects attended our research center for the
pharmacokinetic studies. All subjects had to abstain from al-
cohol consumption for at least 24 h before the measurements,
since alcohol can inhibit ENT transport [15]. The morning
doses of both metformin and dipyridamole on the days of
serial blood sampling were given under supervision at our
research center. To ensure optimal dipyridamole exposure to
the gastrointestinal ENT transporters, the dipyridamole dose
was administered 1 h before the metformin dose. After intake
of the dipyridamole dose, the volunteers were allowed to have
breakfast. Lunch was served no earlier than 4 h after metfor-
min dosing and participants received a snack no earlier than
2 h after lunch.
Pharmacokinetic sampling and safety assessments
Blood samples for the assessment of pharmacokinetic param-
eters of metformin were collected during a 10-h period at t=0
(pre-dose), 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 h after the
intake of the morning dose of metformin. These time points
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were chosen because the Tmax of metformin is approximately
2.5 h. Blood samples were collected in heparinized tubes and
centrifuged for 10 min at 3000 rpm (1700g) at 20 °C. Plasma
was transferred to polypropylene tubes and stored at −80 °C
until further analysis. Subjects were asked about the occur-
rence of adverse events at each visit day.
Compliance
Participants were asked to return the package of their study
medication on both study days. Compliance to medication
was monitored by counting the remaining tablets on each
study day.




Pharmacokinetic parameters for metformin were calculated by
noncompartmental methods using the WinNonlin software
package (version 6.3; Pharsight, Mountain View, CA) and
the linear log-trapezoidal rule. Based on the individual plasma
concentration-time data, the following pharmacokinetic pa-
rameters of metformin were determined: AUC0–10h, the ex-
trapolated AUC from 0 to 12 h after intake (AUC0–12h),
Cmax, Tmax, V/F, CL/F and the apparent elimination half-life
(T1/2). C12h was extrapolated by log-linear extrapolation using
lambda z from the last measured concentration (C10h).
Pharmacokinetic parameters are reported as geometric means
with CV%. Geometric mean ratios (GMRs) of the pharmaco-
kinetic parameters of the test treatment [combination metfor-
min+dipyridamole] versus the reference treatment [metfor-
min alone] and 90 % CI were calculated after log transforma-
tion of within-subject ratios using a mixed effects bioequiva-
lence module in WinNonlin/Phoenix.
Sample size and statistical analysis
For the identification of a clinically relevant drug interaction,
the bioequivalence approach was used, as described previous-
ly [16]. The main pharmacokinetic parameter to be evaluated
in this respect is the exposure to metformin, expressed as
AUC0–12h. This pharmacokinetic parameter and the Cmax are
considered to be the primary measures in this study. Sample
size calculation was performed using the method for two-
period designs of Diletti et al. [17]. The required sample size
was calculated (power of 80 %) assuming no difference in the
AUC of metformin with or without dipyridamole and an esti-
mated intra-subject coefficient of variation of the AUC values
for metformin of 19 %, as reported in other pharmacokinetic
studies with metformin in healthy volunteers [7, 18]. The re-
quired number of participants was 16. Taking dropouts into
account, a total of 18 subjects were included.
Results
Baseline characteristics
We included 18 subjects. One participant withdrew during the
study due to difficulties with venous sampling. This partici-
pant was only included in the safety analysis. Therefore, 17
subjects finished the trial protocol (Suppl. Fig. 1) and were
included in the analysis of pharmacokinetic parameters.
Baseline characteristics are presented in Table 1.
Compliance
The compliance with both metformin and dipyridamole treat-
ment of all subjects was excellent, as indicated by their state-
ments about the intake of the drug doses and the number of
tablets counted on each visit day. All subjects took their study
medication according to protocol, without missing a dose.
Evaluation of steady state
Mean (SD) trough plasma concentrations of both metformin
and dipyridamole collected on the third treatment day and the
morning of the fourth treatment day (day of serial blood
Table 1 Baseline characteristics
Age, years 23 (range 20–25)
Gender
Male 9 (53 %)
Female 8 (47 %)
Body mass index, kg/m2 22.1 ± 3.0
Blood pressure, mmHg
Systolic 131 ± 9
Diastolic 80± 6
Heart rate, beats/min 68± 8
Smoking 0 (0 %)
Alcohol consumption
≤2 units per day 15 (88 %)
>2 units per day 2 (12 %)
Laboratory values at screening
Glucose, mmol/L 5.1 ± 1.0
Creatinin, μmol/L 73± 13
GFR (MDRD), ml/min/1.73 m2 81± 14
Data are mean ± SD (except for age, mean (range)) or number (%) unless
stated otherwise
GRF glomerular filtration rate, MDRD modification of diet in renal
disease
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collection) showed that subjects were adherent and that steady
state conditions for both metformin and dipyridamole were
reached (Supplementary Table 1).
Metformin pharmacokinetics
The pharmacokinetic parameters and the plasma
concentration-time curves of metformin in the presence and
absence of dipyridamole are shown in Table 2 and Fig. 1. All
90 % confidence intervals fell within the 80–125 % bioequiv-
alence criterium. This means that dipyridamole did not affect
Cmax and AUC0–12h of metformin.
Adverse events and safety assessments
The study medication was generally well tolerated, and no
serious adverse events occurred. In the metformin-
dipyridamole treatment arm, 13 subjects (77 %) reported
headache and 8 subjects (47 %) reported mild, self-limiting
gastrointestinal discomfort, mostly diarrhea. One person de-
veloped a phlebitis of his arm after removal of the cannula. In
the metformin-only group, 8 subjects (47 %) reported mild
and self-limiting gastrointestinal discomfort, mostly diarrhea.
There was no headache reported in this group. One subject
reported the occurrence of vivid nightmares, considered not
related to the study medication. Adverse events occurred
mostly within several hours after start of the study medication,
were mild (all were classified as grade 1), and self-limiting.
Discussion
We tested the hypothesis that dipyridamole reduces the bio-
availability of metformin after oral administration by inhibi-
tion of the luminal ENT4 in the small intestine. In a classical
randomized crossover pharmacokinetic interaction study in
healthy subjects, there was no effect of co-administered
slow-release dipyridamole on Cmax and AUC0–12h of metfor-
min. As such, we can conclude that concomitant treatment
with slow-release dipyridamole does not relevantly affect the
plasma exposure to metformin. This finding is of great impor-
tance since many patients with type 2 diabetes mellitus who
have suffered a stroke or transient ischemic attack are being
treated with both of these drugs.
Our hypothesis that dipyridamole limits intestinal absorp-
tion of metformin after oral intake was driven by the following
observations. First, ENT4 is important in the luminal uptake
of metformin [7, 8]. Secondly, dipyridamole significantly in-
hibits ENT4-mediated substrate transport with relevant IC50
values [14]. Thirdly, genetic variations in the gene encoding
ENT4 affect steady-state plasma levels of metformin, empha-
sizing that this transporter is important for metformin uptake
[19]. Based on these findings, concomitant use of metformin
and dipyridamole may result in lower systemic exposure to
metformin which may impact on serum glucose.
In contrast to our hypothesis, we observed no significant
impact of dipyridamole on plasma exposure to metformin in
clinical relevant doses, as reflected by AUC0–12h and Cmax.
There are several potential explanations as to why
dipyridamole does not limit intestinal absorption of metfor-
min. First, a reduced ENT4-mediated uptake of metformin
might be compensated for by an increased absorption by al-
ternative intestinal transporters that are not affected by
dipyridamole. Human small intestine contains detectable
Table 2 Comparison of steady
state pharmacokinetic parameters
of metformin with or without co-










AUC0-12h (ng×h/mL) 7600 (19) 7600 (19) 100 (93–108)
AUC0-10h (ng×h/mL) 7100 (18) 7000 (19) 99 (93–107)
CL/F (L/h) 66 (19) 66 (19) 100 (93–107)
V/F (L) Winnonlin 340 (26) 370 (40) 108 (96–120)
T1/2, desc (h) Winnonlin 3.6 (25) 3.9 (36) 108 (99–118)
Tmax (h) 3 (1–4) 3.5 (2.5–6)
Cmax (ng/mL) 1100 (19) 1100 (19) 101 (95–107)
Results of noncompartmental analysis; for Tmax, median and range are reported
GM geometric mean
Fig. 1 Plasma metformin concentrations (geometric mean ±CV%)
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messenger RNA (mRNA) expression of OCT1-3, OCTN1-2,
and ENT4 [8, 20, 21]. Based on earlier literature, only OCT3
and ENT4 appear to be localized on the apical border of the
enterocytes and could therefore play a role in intestinal ab-
sorption. More recently, apical expression of the serotonin
reuptake transporter (SERT) and OCTN1 in enterocytes was
demonstrated, which may also transport metformin [22–24].
An alternative explanation was provided by Proctor et al., who
reported significant paracellular uptake of metformin [25].
These experiments, however, were performed in vitro in
Caco-2 cells, which differ importantly from the physiological
in vivo situation in human small intestine. Finally, although
the IC50 value of the ENT4 for dipyridamole is in the con-
centration range that is obtained in plasma after oral
dipyridamole administration, we are not informed about the
luminal concentration of dipyridamole at the site of metformin
absorption. A potential mechanism that could increase absorp-
tion of metformin could be the modulation of the intraluminal
pH by dipyridamole: the extended release preparation of
dipyridamole contains tartaric acid. As dipyridamole is a poor-
ly soluble weak base that shows pH-dependent absorption,
this formulation should provide a sufficiently acidic local mi-
lieu within the basic pH environment of the intestine to pro-
mote absorption [26]. Theoretically, this could have been fa-
vorable for ENT4-mediated metformin transport, which is
greatly stimulated by acidic pH [8].
Study medication was well tolerated and subjects experi-
enced only mild side effects. The occurrence of headache was
associated with use of dipyridamole, while gastrointestinal
discomfort was related to metformin [27, 28]. This mainly
involved mild and self-limiting diarrhea in the first days of
metformin treatment. We think it is unlikely that a potentially
shorter gastrointestinal passage time relevantly affected the
results of our study, since diarrhea occurred to a similar extent
in both treatment arms, and in most patients, it was restricted
to the first few days of metformin intake.
There are a few potential limitations of our study. First,
genetic variation in the genes encoding for the various met-
formin transporters, including ENT4 and OCT1-2, have been
linked previously to the altered pharmacokinetic and pharma-
codynamic response tometformin, but we did not perform any
genotyping of the relevant transporters. Secondly, we did not
collect urine from the subjects. This would have enabled us to
more directly estimate the effect of dipyridamole on metfor-
min elimination.
In conclusion, co-administration of dipyridamole at thera-
peutic dosages to healthy volunteers does not have a clinically
relevant effect on metformin plasma steady-state exposure.
This observation is reassuring for patients who are treated with
this combination of drugs.
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